Document is current
Any future updates will be listed below
-
Authors
Wu, Guojin
Xu, Yixiang
Schultz, Robbie D.
Chen, Heyu
Xie, Jingjing
Deng, Mi
Liu, Xiaoye
Gui, Xun
John, Samuel
Lu, Zhigang
Arase, Hisashi https://orcid.org/0000-0002-1153-3166
Zhang, Ningyan https://orcid.org/0000-0002-4348-2180
An, Zhiqiang https://orcid.org/0000-0001-9309-2335
Zhang, Cheng Cheng https://orcid.org/0000-0003-4763-3887
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA248736)
Cancer Prevention and Research Institute of Texas (RP180435, RP150551, RP190561)
- License Information
-
More Information
Article History
Received: 25 October 2020
Accepted: 24 August 2021
First Online: 11 November 2021
Competing interests
: The Board of Regents of the University of Texas System has filed a patent application covering ‘Methods for identifying LILRB-blocking antibodies’. C.C.Z., G.W., H.C., M.D., Z.A. and N.Z. are listed as inventors. The patent application has been exclusively licensed to Immune-Onc Therapeutic, Inc. by the Board of Regents of the University of Texas System. Z.A., N.Z. and C.C.Z. hold equity in and have Sponsored Research Agreements with Immune-Onc Therapeutics, Inc. Z.A. is a Scientific Advisory Board member with Immune-Onc Therapeutics, Inc. The remaining authors declare no competing interests.
